Cardiol Therapeutics Inc (CRDL) COM NPV CL A
Sell:1.68 CADBuy:1.71 CAD
0.09 CAD
(5.03%)
- This stock can be held in a
Stocks and Shares ISA0.09 CAD
(5.03%)0.09 CAD
(5.03%)Company Information
About this company
Cardiol Therapeutics Inc. is a Canada-based clinical-stage life sciences company focused on developing anti-inflammatory and anti-fibrotic therapies for the treatment of heart disease. The Company's lead small-molecule drug candidate, CardiolRx (cannabidiol) oral solution, is pharmaceutically manufactured and in clinical development for use in the treatment of heart disease. It holds investigational new drug application authorization from the United States Food and Drug Administration (US FDA) to conduct clinical studies to evaluate the efficacy and safety of CardiolRx in two diseases affecting the heart: recurrent pericarditis and acute myocarditis. The MAVERIC Program in recurrent pericarditis, an inflammatory disease, comprises the completed Phase II MAvERIC-Pilot study (NCT05494788) and the ongoing Phase III MAVERIC trial (NCT06708299). The Company is also developing CRD-38, a novel subcutaneously administered drug formulation intended for use in heart failure.
Key people
Key facts
- EPICCRDL
- LocationCanada
- SectorHealthcare
- IndustryBiotechnology & Drugs
- ISINCA14161Y2006
- Market capCA$148.11m
- Employees18
- Shares in issue82.65m
- ExchangeToronto Stock Exchange
- Index
- Website
Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Overview data is sourced from Refinitiv.